| Serial Number | 90138790 |
| Word Mark | AEGLEA |
| Filing Date | Wednesday, August 26, 2020 |
| Status | 606 - ABANDONED - NO STATEMENT OF USE FILED |
| Status Date | Monday, June 3, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, September 7, 2021 |
| Goods and Services | Pharmaceutical preparations for the treatment of rare genetic diseases; pharmaceutical preparations for the treatment of Arginase 1 deficiency; pharmaceutical preparations for the treatment of cancer; biopharmaceutical preparations for the treatment of rare genetic diseases; biopharmaceutical preparations for the treatment of Arginase 1 deficiency; biopharmaceutical preparations for the treatment of cancer; biotherapeutic preparations for the treatment of rare genetic diseases; biotherapeutic preparations for the treatment of Arginase 1 deficiency; biotherapeutic preparations for the treatment of cancer; biotherapeutic preparations and substances for the treatment of rare genetic diseases; biotherapeutic preparations and substances for the treatment of Arginase 1 deficiency; biotherapeutic preparations and substances for the treatment of cancer; enzyme replacement therapy preparations for medical purposes; pharmaceutical preparations for the prevention and treatment of infectious diseases and immunological diseases; biopharmaceutical preparations for the prevention and treatment of infectious diseases and immunological diseases; pharmaceutical preparations for the treatment of homocystinuria; biopharmaceutical preparations for the treatment of homocystinuria; biotherapeutic preparations for the treatment of homocystinuria |
| Goods and Services | Scientific research in the fields of pharmaceuticals, biopharmaceuticals, medicine, biologics, biotherapeutics, biosimilars, enzyme replacement therapeutics, and therapeutics, all for the treatment of rare genetic diseases, Arginase 1 deficiency, cancer, immunological diseases, homocystinuria, and infectious diseases; medical and scientific research in the field of pharmaceutical and biopharmaceutical treatment of rare genetic diseases, Arginase 1 deficiency, cancer, immunological diseases, homocystinuria, and infectious diseases; providing medical and scientific research information, consultancy, and advisory services, all in the fields of pharmaceuticals, biopharmaceuticals, medicine, biologics, biotherapeutics, biosimilars, enzyme replacement therapeutics, and therapeutics treatments, and all for the treatment of rare genetic diseases, Arginase 1 deficiency, cancer, immunological diseases, homocystinuria, and infectious diseases; Design, engineering, research, development and testing services, all for medical research purposes in the fields of cancer, rare genetic disease, Arginase 1 deficiency treatments, immunological diseases, homocystinuria, and infectious diseases |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, September 29, 2020 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, September 29, 2020 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Aeglea BioTherapeutics, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Austin, TX 78746 |
| Party Name | Aeglea BioTherapeutics, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Austin, TX 78746 |
| Event Date | Event Description |
| Saturday, August 29, 2020 | NEW APPLICATION ENTERED |
| Tuesday, September 29, 2020 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, December 24, 2020 | ASSIGNED TO EXAMINER |
| Thursday, December 31, 2020 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Thursday, December 31, 2020 | NON-FINAL ACTION WRITTEN |
| Thursday, December 31, 2020 | NON-FINAL ACTION E-MAILED |
| Tuesday, June 29, 2021 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, June 30, 2021 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, June 29, 2021 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, August 18, 2021 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, September 7, 2021 | PUBLISHED FOR OPPOSITION |
| Tuesday, September 7, 2021 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Saturday, July 31, 2021 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Tuesday, November 2, 2021 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Friday, April 29, 2022 | SOU EXTENSION 1 FILED |
| Friday, April 29, 2022 | SOU TEAS EXTENSION RECEIVED |
| Friday, April 29, 2022 | SOU EXTENSION 1 GRANTED |
| Tuesday, May 3, 2022 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, November 1, 2022 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, November 1, 2022 | SOU EXTENSION 2 FILED |
| Tuesday, November 1, 2022 | SOU EXTENSION 2 GRANTED |
| Monday, May 1, 2023 | SOU TEAS EXTENSION RECEIVED |
| Thursday, November 3, 2022 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, May 1, 2023 | SOU EXTENSION 3 FILED |
| Monday, May 1, 2023 | SOU EXTENSION 3 GRANTED |
| Wednesday, May 3, 2023 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Thursday, November 2, 2023 | SOU TEAS EXTENSION RECEIVED |
| Thursday, November 2, 2023 | SOU EXTENSION 4 FILED |
| Thursday, November 2, 2023 | SOU EXTENSION 4 GRANTED |
| Thursday, May 16, 2024 | ASSIGNED TO EXAMINER |
| Monday, June 3, 2024 | ABANDONMENT - NO USE STATEMENT FILED |
| Saturday, November 4, 2023 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |